About Us

BD acquired TriPath Imaging Inc., a global cancer diagnostics company, on December 20, 2006. BD's acquisition of TriPath was a natural choice given the collaborative relationship that our two companies established in 2001 to develop and commercialize molecular diagnostic products for various cancers, including cervical, breast, ovarian and prostate.

The acquisition provides the breadth of complementary technologies and resources required to continue to drive the cervical cancer screening business and to accelerate the successful market introduction of innovative molecular diagnostic products for cancers of the cervix, breast, ovary and prostate.

BD Diagnostics - TriPath offers products for cervical cytology screening. Our BD SurePath™ Pap test, BD PrepStain™ Slide Processor, BD FocalPoint™ Slide Profiler and BD FocalPoint™ GS Imaging System, together, provide an integrated solution for sample preparation, processing, staining, and computer-assisted imaging of liquid-based Pap testing.

In addition to the cervical cytology products, BD markets BD ProEx™ C reagents for the detection of aberrant S-phase induction and BD CytoRich™ preservative for non-gynecological applications.